EXENDUBEK Trademark

Trademark Overview

On Monday, May 18, 2020, a trademark application was filed for EXENDUBEK with the United States Patent and Trademark Office. The USPTO has given the EXENDUBEK trademark a serial number of 88921841. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 24, 2024. This trademark is owned by Celgene Corporation. The EXENDUBEK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
exendubek

General Information

Serial Number88921841
Word MarkEXENDUBEK
Filing DateMonday, May 18, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 23, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 3, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Thursday, May 21, 2020NEW APPLICATION ENTERED
Wednesday, June 3, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, August 15, 2020ASSIGNED TO EXAMINER
Wednesday, August 19, 2020NON-FINAL ACTION WRITTEN
Wednesday, August 19, 2020NON-FINAL ACTION E-MAILED
Wednesday, August 19, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, February 11, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 11, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 12, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, February 13, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 3, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 23, 2021PUBLISHED FOR OPPOSITION
Tuesday, March 23, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 18, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, December 23, 2021PETITION TO REVIVE-GRANTED
Monday, January 31, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, November 18, 2021SOU EXTENSION 1 FILED
Monday, December 20, 2021ABANDONMENT - NO USE STATEMENT FILED
Monday, December 20, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Thursday, December 23, 2021TEAS PETITION TO REVIVE RECEIVED
Thursday, December 23, 2021SOU EXTENSION RECEIVED WITH TEAS PETITION
Friday, December 24, 2021NOTICE OF REVIVAL - E-MAILED
Monday, January 31, 2022SOU EXTENSION 1 GRANTED
Tuesday, February 1, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 9, 2022SOU TEAS EXTENSION RECEIVED
Monday, May 9, 2022SOU EXTENSION 2 FILED
Monday, May 9, 2022SOU EXTENSION 2 GRANTED
Wednesday, May 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 28, 2023SOU TEAS EXTENSION RECEIVED
Friday, April 28, 2023SOU EXTENSION 4 FILED
Friday, April 28, 2023SOU EXTENSION 4 GRANTED
Tuesday, May 2, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 8, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 9, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 9, 2022SOU EXTENSION 3 FILED
Wednesday, November 9, 2022SOU EXTENSION 3 GRANTED
Wednesday, November 8, 2023SOU EXTENSION 5 FILED
Monday, November 13, 2023SOU EXTENSION 5 GRANTED
Tuesday, November 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 24, 2024ABANDONMENT - NO USE STATEMENT FILED
Friday, July 12, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

exendubek diseases pharmaceutical human preparations anti system disease cancer disorders namely